title: Adalimumab in rheumatoid arthritis after failed infliximab and/or etanercept therapy: experience with 18 patients.
authors.forename: O
authors.initials: O
authors.lastname: Brocq
authors.forename: C
authors.initials: C
authors.lastname: Albert
authors.forename: C
authors.initials: C
authors.lastname: Roux
authors.forename: D
authors.initials: D
authors.lastname: Gerard
authors.forename: V
authors.initials: V
authors.lastname: Breuil
authors.forename: L Euller
authors.initials: LE
authors.lastname: Ziegler
mesh_terms: D000068879:Adalimumab; D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D017211:Treatment Failure
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000069285:Infliximab; D000068879:Adalimumab; D000068800:Etanercept